Related Experiment Video
Updated: May 13, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
[Development of an adenovirus vector containing a hepatitis C virus expression cassette and its application]
Takeshi Yoshida1, Masuo Kondoh, Hiroyuki Mizuguchi
1Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Insights
Researchers developed a novel adenovirus (Ad) vector for delivering the Hepatitis C virus (HCV) genome. This new system offers a more efficient method for studying HCV infection and developing antiviral therapies.
Area of Science:
- Virology
- Hepatology
- Gene Therapy
Background:
- Hepatitis C virus (HCV) infects 170 million globally, increasing risks for chronic hepatitis, cirrhosis, and liver cancer.
- Efficient delivery of the HCV genome into hepatocytes is crucial for understanding viral mechanisms and developing treatments.
- Current methods like electroporation and plasmid transduction have limitations in efficiency and convenience.
Purpose of the Study:
- To develop a novel adenovirus (Ad) vector system for expressing and delivering the Hepatitis C virus (HCV) genome.
- To establish a more efficient and convenient tool for HCV research compared to existing methods.
- To facilitate future studies on HCV replication, pathogenesis, and antiviral drug screening.
Main Methods:
- Construction and preparation of an Adenovirus (Ad) vector designed to express the Hepatitis C virus (HCV) genome.
- Utilizing established Adenovirus (Ad) vector technology, commonly employed in clinical gene therapy.
Main Results:
- Successfully prepared an Adenovirus (Ad) vector expressing the Hepatitis C virus (HCV) genome.
- Demonstrated the potential of the Ad vector system for efficient HCV genome delivery.
Conclusions:
- The developed Ad vector represents a promising new system for HCV genome delivery.
- This novel vector system is expected to advance research in Hepatitis C virus (HCV) infection, replication, and the development of anti-HCV drugs.
Abstract:
Hepatitis C virus (HCV) is a hepatotropic member of the Flaviviridae family and contains a 9.6 kb positive-sense RNA genome. Approximately 170-million people are infected with HCV worldwide. These people face increased risks of chronic hepatitis, cirrhosis and hepatocellular carcinoma compared with the general population. Transduction of the HCV genome into hepatocytes is essential for understanding the mode of action of HCV infection, and for preparing HCV, evaluating HCV replication, and screening anti-HCV drugs. Although electroporation of in vitro-synthesized HCV genome and transduction of plasmid vectors containing the HCV genome are widely used in HCV research, a more convenient system with higher transduction efficiency is needed. Among viral transduction systems, adenovirus (Ad) vector is one of the most efficient and convenient systems; Ad vector has been widely used in clinical gene therapies. Therefore, Ad vector is a promising system for the delivery of the HCV genome; however, an Ad vector expressing the HCV genome has never been developed. We here describe the preparation of an Ad vector expressing the HCV genome, and outline future directions of HCV research using this vector system.
